PURPOSE: Although adolescents are at high risk for human immunodeficiency virus (HIV) infection, they have not been, included in HIV vaccine trials. METHODS: In preparation for enrollment in HIV vaccine trials, 100 HIV-negative adolescents aged 14-17 years from Cape Town were recruited into a cohort. HIV, syphilis, pregnancy testing, and sexual risk questionnaires were conducted at varying intervals for a year. RESULTS: The mean age of the participants was 15 years, and 70% of them were female. Recruitment was completed within 3 months. Retention was found to be 82% at 1-year follow-up. The main reasons for dropout were as follows: relocation to other communities, phlebotomy, and visit frequency. In a Cox proportional hazards model, only female gender was significantly associated with retention. No change in reported sexual risk occurred, but the proportion of individuals who were aware of their partner's HIV status was significantly higher (17% at baseline, 83% at 1-year follow-up; p < .001). Five pregnancies were reported during follow-up. CONCLUSIONS: To our knowledge, this is the first prospective adolescent HIV-prevention cohort in Southern Africa. Despite reports of risky sexual behaviors and high pregnancy rates, HIV seroconversions did not occur in the retained cohort. HIV-prevention trials with high-risk adolescents will require rigorous efforts to prevent future pregnancies, and may require risk eligibility criteria. Retention may improve with transport provision, visits with incentives, and efforts to retain males.
PURPOSE: Although adolescents are at high risk for human immunodeficiency virus (HIV) infection, they have not been, included in HIV vaccine trials. METHODS: In preparation for enrollment in HIV vaccine trials, 100 HIV-negative adolescents aged 14-17 years from Cape Town were recruited into a cohort. HIV, syphilis, pregnancy testing, and sexual risk questionnaires were conducted at varying intervals for a year. RESULTS: The mean age of the participants was 15 years, and 70% of them were female. Recruitment was completed within 3 months. Retention was found to be 82% at 1-year follow-up. The main reasons for dropout were as follows: relocation to other communities, phlebotomy, and visit frequency. In a Cox proportional hazards model, only female gender was significantly associated with retention. No change in reported sexual risk occurred, but the proportion of individuals who were aware of their partner's HIV status was significantly higher (17% at baseline, 83% at 1-year follow-up; p < .001). Five pregnancies were reported during follow-up. CONCLUSIONS: To our knowledge, this is the first prospective adolescent HIV-prevention cohort in Southern Africa. Despite reports of risky sexual behaviors and high pregnancy rates, HIV seroconversions did not occur in the retained cohort. HIV-prevention trials with high-risk adolescents will require rigorous efforts to prevent future pregnancies, and may require risk eligibility criteria. Retention may improve with transport provision, visits with incentives, and efforts to retain males.
Authors: Paulette D Stanford; Dina A Monte; Felecia M Briggs; Patricia M Flynn; Mary Tanney; Jonas H Ellenberg; Kathy L Clingan; Audrey Smith Rogers Journal: J Adolesc Health Date: 2003-03 Impact factor: 5.012
Authors: Heather B Jaspan; Alan J Flisher; Landon Myer; Catherine Mathews; Chris Seebregts; Jessica R Berwick; Robin Wood; Linda-Gail Bekker Journal: J Adolesc Date: 2006-12-21
Authors: Kawango E Agot; James N Kiarie; Huong Q Nguyen; Jacob O Odhiambo; Tom M Onyango; Noel S Weiss Journal: J Acquir Immune Defic Syndr Date: 2007-01-01 Impact factor: 3.731
Authors: Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin Journal: Lancet Date: 2004 Nov 13-19 Impact factor: 79.321
Authors: Nora E Rosenberg; Margaret W Gichane; Dhrutika Vansia; Twambilile Phanga; Nivedita L Bhushan; Linda-Gail Bekker; Audrey E Pettifor Journal: AIDS Behav Date: 2020-05
Authors: Jonathan E Volk; Nancy A Hessol; Glenda E Gray; James G Kublin; Gavin J Churchyard; Koleka Mlisana; Maphoshane Nchabeleng; Susan P Buchbinder; Linda-Gail Bekker Journal: Int J STD AIDS Date: 2013-10-08 Impact factor: 1.359
Authors: M Florencia Etcheverry; Jennifer L Evans; Emilia Sanchez; Eva Mendez-Arancibia; Mercé Meroño; José M Gatell; Kimberly Page; Joan Joseph Journal: Hum Vaccin Immunother Date: 2013-01-04 Impact factor: 3.452
Authors: Andrea S Mendelsohn; Katherine Gill; Rebecca Marcus; Dante Robbertze; Claudine van de Venter; Eve Mendel; Landisiwe Mzukwa; Linda-Gail Bekker Journal: South Afr J HIV Med Date: 2018-11-26 Impact factor: 2.744
Authors: Smritee Dabee; Shaun L Barnabas; Katie S Lennard; Shameem Z Jaumdally; Hoyam Gamieldien; Christina Balle; Anna-Ursula Happel; Brandon D Murugan; Anna-Lise Williamson; Nonhlanhla Mkhize; Janan Dietrich; David A Lewis; Francesca Chiodi; Thomas J Hope; Robin Shattock; Glenda Gray; Linda-Gail Bekker; Heather B Jaspan; Jo-Ann S Passmore Journal: PLoS One Date: 2019-04-04 Impact factor: 3.240
Authors: Elizabeth E Tolley; Sylvia Kaaya; Anna Kaale; Anna Minja; Doreen Bangapi; Happy Kalungura; Jennifer Headley; Joy Noel Baumgartner Journal: J Int AIDS Soc Date: 2014-09-08 Impact factor: 5.396
Authors: Rong Pei; Chunnong Ji-Ke; Shujuan Yang; Lei Nan; Qixing Wang; Suhua Zhang; Qiang Liao; Gang Yu; Lin Xiao; Yuhan Gong; Jianxin Zhang; Ke Wang; Ju Wang; Zhuo Wang Journal: Medicine (Baltimore) Date: 2018-09 Impact factor: 1.817